A Phase 3 interventional study of FYB203 (Proposed aflibercept biosimilar) and Eylea® (Aflibercept) in Neovascular Age-related Macular Degeneration, sponsored by Bioeq GmbH. Completed at 66 sites in 9 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-11-13.
Sponsored by Bioeq GmbH · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 8th largest by enrollment, is one of 2 that started in 2020, is one of 18 in phase 3, and was the 47th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 27
First in 2005; this study’s year is marked. 2 started in 2020.
This study's enrollment of 434 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 66 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 66 have an industry lead sponsor. The 10 most frequent:
Bioeq GmbH is the lead sponsor of 3 studies on the registry; none are open to participants now.
Bioeq GmbH has 2 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 66 studies testing aflibercept in Macular Degeneration, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-masked, multicenter study to evaluate the efficacy and safety of FYB203 compared to Eylea® in patients with neovascular age related macular degeneration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female:
Female: A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:
Exclusion Criteria:
Patients are not eligible for the study if any of the following criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive intravitreal (IVT) injections of FYB203 as detailed in the protocol.
Drug: FYB203 (Proposed aflibercept biosimilar)
Patients will receive intravitreal (IVT) injections of Eylea® as detailed in the protocol.
Drug: Eylea® (Aflibercept)
Patients will receive 1 IVT injection of FYB203 in the study eye only every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
Patients will receive 1 IVT injection of Eylea® in the study eye only every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
Evaluate and Compare Functional Changes in Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at Week 8 of Treatment With FYB203 or Eylea Compared to Baseline.
Changes in Best Corrected Visual Acuity (BCVA) by ETDRS letters from the Baseline Visit (Visit 1) to Week 8 (Visit 3) were assessed. This involved measuring the number of letters a participant could correctly read using the study eye on the ETDRS chart. An increase in the number of ETDRS letters from baseline signifies an improvement in visual acuity of the study eye. The change from baseline was calculated as the observed post-baseline value minus the baseline value.
Time frame: Week 8
Evaluate and Compare Functional Changes of the Retina by BCVA Over Time
Change of BCVA by ETDRS letters over the whole study from Baseline Visit (Visit 1) to Week 24 (Visit 5) and Week 56 (Visit 9) - FAS
Time frame: Through study completion, until Week 56 (Visit 9)
Evaluate and Compare Changes in Foveal Center Point (FCP) Retinal Thickness
Change from Baseline Visit (Visit 1) in foveal center point FCP retinal thickness to Week 4 (Visit 2), Week 24 (Visit 5) and Week 56 (Visit 9) - FAS
Time frame: Through study completion, until Week 56 (Visit 9)
Evaluate and Compare the Proportion of Patients Who Gain or Lose ≥ 5, 10, and 15 Early Treatment Diabetic Retinopathy Study (ETDRS) Letters Compared to Baseline
Proportion of patients who gain or lose ≥ 5, 10, or 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters from Baseline Visit (Visit 1) to Week 24 (Visit 5) and Week 56 (Visit 9) - FAS
Time frame: Through study completion, until Week 56 (Week 9)
Evaluate and Compare the Absence of Disease Activity (Fluid-free Macula) Over Time
Percentage of patients with fluid-free macula at Baseline (Visit 1), Week 24 (Visit 5), Week 56 (Visit 9) - FAS
Time frame: Through study completion, until Week 56 (Visit 9)
Evaluate and Compare Systemic Free Aflibercept Concentrations in a Subgroup of up to 60 Patients (up to 30 Per Arm)
Systemic concentrations (close to maximum concentration \[Cmax\]) of free aflibercept in a subgroup at selected sites - PKS: \- 48 hours after the 3rd dose (Visit 3a)
Time frame: At Baseline and Visit 3a (48 hours after the 3rd dose)
Evaluate and Compare Change in Vision-related Functioning and Well-being Measured by National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25)
Change from Baseline Visit (Visit 1) in vision-related functioning and well-being measured by National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) to Week 24 (Visit 5) and Week 56 (Visit 9) - FAS. The NEI VFQ-25 includes 12 subscales (e.g., general vision, ocular pain, driving, peripheral vision) scored from 0 to 100, where higher scores indicate better functioning. Subscales are averaged to produce a composite score, excluding the general health subscale. Both subscale and composite scores range from 0 (worst) to 100 (best), representing the percentage of the highest possible score achieved.
Time frame: Through study completion, until Week 56 (Visit 9)
Evaluate and Compare the Immunogenic Profile (Anti-drug Antibodies [ADAs]) in Serum
Number of patients with anti-drug antibodies (ADAs) at Baseline (Visit 1), Week 24 (Visit 5) and Week 56 (Visit 9) - SAF
Time frame: Through study completion, until Week 56 (Visit 9)
Frequency of Local and Systemic Adverse Events (AEs) and Serious Adverse Events (SAEs)
Frequency of local and systemic adverse events (AEs) and serious adverse events (SAEs) - SAF
Time frame: Through study completion, until Week 56 (Visit 9)
| Milestone | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) |
|---|---|---|
| Started | 215 | 219 |
| Completed | 196 | 206 |
| Not completed | 19 | 13 |
Changes in Best Corrected Visual Acuity (BCVA) by ETDRS letters from the Baseline Visit (Visit 1) to Week 8 (Visit 3) were assessed. This involved measuring the number of letters a participant could correctly read using the study eye on the ETDRS chart. An increase in the number of ETDRS letters from baseline signifies an improvement in visual acuity of the study eye. The change from baseline was calculated as the observed post-baseline value minus the baseline value.
| letters | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) |
|---|---|---|
| Evaluate and Compare Functional Changes in Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) Letters at Week 8 of Treatment With FYB203 or Eylea Compared to Baseline. | 6.6 ± 0.73 | 5.6 ± 0.73 |
Change of BCVA by ETDRS letters over the whole study from Baseline Visit (Visit 1) to Week 24 (Visit 5) and Week 56 (Visit 9) - FAS
| letters | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) |
|---|---|---|
| to Week 24 (Visit 5) | 7.0 ± 9.45 | 6.6 ± 9.51 |
| to Week 56 (Visit 9) | 8.3 ± 10.37 | 6.6 ± 11.47 |
Change from Baseline Visit (Visit 1) in foveal center point FCP retinal thickness to Week 4 (Visit 2), Week 24 (Visit 5) and Week 56 (Visit 9) - FAS
| μm | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) |
|---|---|---|
| to Week 4 (Visit 2) | -163.9 ± 142.17 | -168.4 ± 126.36 |
| to Week 24 (Visit 5) | -165.9 ± 174.98 | -172.4 ± 153.00 |
| to Week 56 (Visit 9) | -188.4 ± 181.08 | -202.4 ± 156.96 |
Proportion of patients who gain or lose ≥ 5, 10, or 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters from Baseline Visit (Visit 1) to Week 24 (Visit 5) and Week 56 (Visit 9) - FAS
| Participants | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) |
|---|---|---|
| to Week 24 (Visit 5) — ≥ 15 letters (gain 15 or more) | 45 | 38 |
| to Week 24 (Visit 5) — ≥ 10 and < 15 letters (gain 10-14) | 41 | 39 |
| to Week 24 (Visit 5) — ≥ 5 and < 10 letters (gain 5-9) | 41 | 47 |
| to Week 24 (Visit 5) — > -5 and < 5 letters (gain or loss up to 4) | 52 | 58 |
| to Week 24 (Visit 5) — > -10 and ≤ -5 letters (loss 5-9) | 12 | 13 |
| to Week 24 (Visit 5) — > -15 and ≤ -10 letters (loss 10-14) | 6 | 2 |
| to Week 24 (Visit 5) — ≤ -15 letters (loss 15 or more) | 4 | 6 |
| to Week 56 (Visit 9) — ≥ 15 letters (gain 15 or more) | 52 | 49 |
| to Week 56 (Visit 9) — ≥ 10 and < 15 letters (gain 10-14) | 43 | 36 |
| to Week 56 (Visit 9) — ≥ 5 and < 10 letters (gain 5-9) | 34 | 39 |
| to Week 56 (Visit 9) — > -5 and < 5 letters (gain or loss up to 4) | 39 | 48 |
| to Week 56 (Visit 9) — > -10 and ≤ -5 letters (loss 5-9) | 12 | 13 |
| to Week 56 (Visit 9) — > -15 and ≤ -10 letters (loss 10-14) | 6 | 7 |
| to Week 56 (Visit 9) — ≤ -15 letters (loss 15 or more) | 2 | 9 |
Percentage of patients with fluid-free macula at Baseline (Visit 1), Week 24 (Visit 5), Week 56 (Visit 9) - FAS
| Participants | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) |
|---|---|---|
| Baseline (Visit 1) — Assessment / Response = Yes | 0 | 0 |
| Baseline (Visit 1) — Assessment / Response = No | 214 | 217 |
| Week 24 (Visit 5) — Assessment / Response = Yes | 71 | 65 |
| Week 24 (Visit 5) — Assessment / Response = No | 127 | 135 |
| Week 56 (Visit 9) — Assessment / Response = Yes | 79 | 100 |
| Week 56 (Visit 9) — Assessment / Response = No | 108 | 98 |
Systemic concentrations (close to maximum concentration \[Cmax\]) of free aflibercept in a subgroup at selected sites - PKS: \- 48 hours after the 3rd dose (Visit 3a)
| ng/mL | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) |
|---|---|---|
| Baseline (Visit 1) | 2.000 ± 0.0000 | 2.000 ± 0.0000 |
| Visit 3a (48h after 3rd dose) | 122.166 ± 30.5161 | 120.112 ± 28.9556 |
Change from Baseline Visit (Visit 1) in vision-related functioning and well-being measured by National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) to Week 24 (Visit 5) and Week 56 (Visit 9) - FAS. The NEI VFQ-25 includes 12 subscales (e.g., general vision, ocular pain, driving, peripheral vision) scored from 0 to 100, where higher scores indicate better functioning. Subscales are averaged to produce a composite score, excluding the general health subscale. Both subscale and composite scores range from 0 (worst) to 100 (best), representing the percentage of the highest possible score achieved.
| score points | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) |
|---|---|---|
| to Week 24 (Visit 5) | 3.8 ± 11.06 | 1.8 ± 10.97 |
| to Week 56 (Visit 9) | 3.8 ± 12.22 | 1.7 ± 12.46 |
Number of patients with anti-drug antibodies (ADAs) at Baseline (Visit 1), Week 24 (Visit 5) and Week 56 (Visit 9) - SAF
| Participants | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) |
|---|---|---|
| Week 1 (Baseline) — Positive | 4 | 3 |
| Week 1 (Baseline) — Negative | 209 | 201 |
| Week 24 (Visit 5) — Positive | 4 | 1 |
| Week 24 (Visit 5) — Negative | 191 | 192 |
| Week 56 (Visit 9) — Positive | 5 | 2 |
| Week 56 (Visit 9) — Negative | 189 | 190 |
Frequency of local and systemic adverse events (AEs) and serious adverse events (SAEs) - SAF
| Participants | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) |
|---|---|---|
| SAEs | 19 | 28 |
| local AEs, study eye | 67 | 75 |
| local AEs, fellow eye | 45 | 48 |
| systemic AEs | 124 | 113 |
Collected over All AEs reported until the final end of study visit at week 56 are included.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FYB203 (Proposed Aflibercept Biosimilar), Systemic AE | 4/215 (1.9%) | 17/215 (7.9%) | 56/215 (26%) |
| Eylea® (Aflibercept), Systemic AE | 1/218 (0.5%) | 23/218 (10.6%) | 46/218 (21.1%) |
| FYB203 (Proposed Aflibercept Biosimilar), Ocular AE, Study Eye | 0/215 (0%) | 2/215 (0.9%) | 44/215 (20.5%) |
| Eylea® (Aflibercept), Ocular AE, Study Eye | 0/218 (0%) | 2/218 (0.9%) | 49/218 (22.5%) |
| FYB203 (Proposed Aflibercept Biosimilar), Ocular AE, Fellow Eye | 0/215 (0%) | 0/215 (0%) | 37/215 (17.2%) |
| Eylea® (Aflibercept), Ocular AE, Fellow Eye | 0/218 (0%) | 3/218 (1.4%) | 32/218 (14.7%) |
| Event | FYB203 (Proposed Aflibercept Biosimilar), Systemic AE | Eylea® (Aflibercept), Systemic AE | FYB203 (Proposed Aflibercept Biosimilar), Ocular AE, Study Eye | Eylea® (Aflibercept), Ocular AE, Study Eye | FYB203 (Proposed Aflibercept Biosimilar), Ocular AE, Fellow Eye | Eylea® (Aflibercept), Ocular AE, Fellow Eye |
|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 4/215 | 1/218 | 0/215 | 0/218 | 0/215 | 0/218 |
| Cardiac failureCardiac disorders | 2/215 | 1/218 | 0/215 | 0/218 | 0/215 | 0/218 |
| COVID-19 pneumoniaInfections and infestations | 1/215 | 2/218 | 0/215 | 0/218 | 0/215 | 0/218 |
| AppendicitisInfections and infestations | 0/215 | 2/218 | 0/215 | 0/218 | 0/215 | 0/218 |
| PneumoniaInfections and infestations | 1/215 | 1/218 | 0/215 | 0/218 | 0/215 | 0/218 |
| BronchitisInfections and infestations | 1/215 | 0/218 | 0/215 | 0/218 | 0/215 | 0/218 |
| Coronavirus infectionInfections and infestations | 1/215 | 0/218 | 0/215 | 0/218 | 0/215 | 0/218 |
| Gallbladder empyemaInfections and infestations | 1/215 | 0/218 | 0/215 | 0/218 | 0/215 | 0/218 |
| Toxic shock syndromeInfections and infestations | 1/215 | 0/218 | 0/215 | 0/218 | 0/215 | 0/218 |
| UrosepsisInfections and infestations | 1/215 | 0/218 | 0/215 | 0/218 | 0/215 | 0/218 |
| Event | FYB203 (Proposed Aflibercept Biosimilar), Systemic AE | Eylea® (Aflibercept), Systemic AE | FYB203 (Proposed Aflibercept Biosimilar), Ocular AE, Study Eye | Eylea® (Aflibercept), Ocular AE, Study Eye | FYB203 (Proposed Aflibercept Biosimilar), Ocular AE, Fellow Eye | Eylea® (Aflibercept), Ocular AE, Fellow Eye |
|---|---|---|---|---|---|---|
| Neovascular age-related macular degenerationEye disorders | 0/215 | 0/218 | 7/215 | 7/218 | 22/215 | 24/218 |
| COVID-19Infections and infestations | 15/215 | 17/218 | 0/215 | 0/218 | 0/215 | 0/218 |
| HypertensionVascular disorders | 15/215 | 9/218 | 0/215 | 0/218 | 0/215 | 0/218 |
| Conjunctival haemorrhageEye disorders | 0/215 | 0/218 | 4/215 | 14/218 | 1/215 | 0/218 |
| NasopharyngitisInfections and infestations | 10/215 | 6/218 | 0/215 | 0/218 | 0/215 | 0/218 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 9/215 | 1/218 | 0/215 | 0/218 | 0/215 | 0/218 |
| Intraocular pressure increasedInvestigations | 0/215 | 0/218 | 7/215 | 9/218 | 2/215 | 1/218 |
| CataractEye disorders | 0/215 | 0/218 | 8/215 | 7/218 | 7/215 | 4/218 |
| Visual acuity reducedEye disorders | 0/215 | 0/218 | 7/215 | 4/218 | 2/215 | 2/218 |
| HeadacheNervous system disorders | 4/215 | 7/218 | 0/215 | 0/218 | 0/215 | 0/218 |
Safety Analysis Set (SAF)
| Age, Continuous(years) | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) | Total |
|---|---|---|---|
| Mean | 73.7 ± 7.72 | 73.3 ± 7.70 | 73.5 ± 7.71 |
| Age, Customized(Participants) | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) | Total |
|---|---|---|---|
| Age, Categorical — Between 18 and 64 years | 17 | 25 | 42 |
| Age, Categorical — Between 65 and 84 years | 181 | 180 | 361 |
| Age, Categorical — >= 85 years | 17 | 13 | 30 |
| Sex: Female, Male(Participants) | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) | Total |
|---|---|---|---|
| Female | 121 | 127 | 248 |
| Male | 94 | 91 | 185 |
| Ethnicity (NIH/OMB)(Participants) | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 5 | 8 |
| Not Hispanic or Latino | 212 | 213 | 425 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 17 | 16 | 33 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 197 | 201 | 398 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | FYB203 (Proposed Aflibercept Biosimilar) | Eylea® (Aflibercept) | Total |
|---|---|---|---|
| Bulgaria | 10 | 11 | 21 |
| Czechia | 34 | 35 | 69 |
| Hungary | 34 | 34 | 68 |
| Israel | 6 | 6 | 12 |
| Italy | 9 | 9 | 18 |
| Japan | 17 | 16 | 33 |
| Poland | 37 | 40 | 77 |
| Russia | 35 | 36 | 71 |
| Ukraine | 33 | 31 | 64 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2020 to primary completion in Jun 2022, 23 months.
Results were first posted in Nov 2025, 3 years 4 months after primary completion.
Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 23 months is close to that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept
Bioeq GmbH